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Butirosin, an aminoglycoside antibiotic pro-
duced by Bacillus circulans, bears the unique
(S)-4-amino-2-hydroxybutyrate (AHBA) side
chain, which protects the antibiotic from
several common resistance mechanisms. The
AHBA side chain is advantageously incorpo-
rated into clinically valuable antibiotics such
as amikacin and arbekacin by synthetic
methods. Therefore, it is of significant interest
to explore the biosynthetic origins of this useful
moiety.We report here that the AHBA side chain
of butirosin is transferred from the acyl carrier
protein (ACP) BtrI to the parent aminoglycoside
ribostamycin as a g-glutamylated dipeptide by
the ACP:aminoglycoside acyltransferase BtrH.
The protective g-glutamyl group is then cleaved
by BtrG via an uncommon g-glutamyl cyclo-
transferase mechanism. The application of this
pathway to the in vitro enzymatic production
of novel AHBA-bearing aminoglycosides is
explored with encouraging implications for the
preparation of unnatural antibiotics via directed
biosynthesis.
INTRODUCTION
The aminoglycosides, a diverse family of bactericidal
compounds that includes kanamycin, neomycin, and gen-
tamicin, among others, exhibit a diversity of established
and potential medicinal activities. Aminoglycosides were
among the first antibiotics in clinical use, and they remain
valuable agents for the treatment of difficult infections,
especially those caused by Gram-negative bacteria such
as Mycobacterium tuberculosis and methicillin-resistant
Staphylococcus aureus (MRSA) [1, 2]. Recent investiga-
tions have revealed the potential utility of aminoglycosides
as antiviral agents, with demonstrated activity against viral
and catalytic RNAs including human immunodeficiency vi-
rus (HIV) [3, 4], the hepatitis delta virus (HDV) ribozyme, the
hammerhead ribozyme, and the group I intron [5]. Further-Chemistry & Biology 14, 3more, aminoglycosides may induce plasmid incompatibil-
ity in bacteria, raising the exciting prospect of drug-
induced reversal of plasmid-mediated antibiotic resis-
tance in some clinical pathogens [6]. The bactericidal
activity of this family of drugs derives from their strong af-
finity for the rRNA of the bacterial ribosome, which leads to
the disruption of protein synthesis by interfering with co-
don fidelity and translocation [7, 8]. Likewise, the antiviral
and antiplasmid activities of aminoglycosides arise from
the affinity of these polycations for nucleic acid strands.
As is the case with all classes of clinical antibiotics, ami-
noglycosides face the problem of resistant pathogens [9,
10]. Although mutation of the ribosomal rRNA has been
shown to effect aminoglycoside resistance in some cases,
clinical resistance is most commonly conferred by the ex-
pression of at least one enzyme that modifies the amino-
glycoside [11] by O-phosphorylation, O-nucleotidylyla-
tion, or N-acylation—all modifications which weaken the
affinity of the drug for RNA. Semisynthetic N-substituted
aminoglycoside derivatives such as amikacin [12] and ar-
bekacin [13], however, are largely unaffected by a number
of common resistance enzymes, and synthetic efforts
have focused on the use of substrate-specific protection
schemes for the stereospecific synthesis of aminoglyco-
side derivatives [14–16]. Engineered biosynthesis by ge-
netic manipulation of aminoglycoside-producing organ-
isms presents an attractive alternative to synthetic
methods for the production of novel antibiotic com-
pounds. For this strategy to be successful, intimate knowl-
edge of the biosynthetic pathways leading to these natural
products is required [17].
The strategy of exploring acyl-aminoglycoside deriva-
tives to sidestep resistance enzymes was initially inspired
by the discovery of the butirosins from Bacillus circulans
[18]. Butirosins A and B are naturally occurring derivatives
of xylostasin and ribostamycin, respectively, which bear
an (S)-4-amino-2-hydroxybutyrate (AHBA) substituent
at the C-1 amine of the central 2-deoxystreptamine
(2-DOS) ring. The butirosins exhibit improved antibiotic
properties over their parent molecules and retain bacteri-
cidal activity toward many aminoglycoside-resistant
strains. The gene cluster encoding the biosynthetic path-
way for butirosin in B. circulans has been sequenced [19,
20] (accession numbers AB097196 and AJ847918), and
comparison to the neomycin cluster from Streptomyces79–386, April 2007 ª2007 Elsevier Ltd All rights reserved 379
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Addition of the Amino Acid Side Chain in ButirosinFigure 1. Biosynthetic Pathway for the AHBA Side Chain in Butirosin
Bold arrows indicate steps elucidated in this paper.fradiae [21] revealed a set of seven genes putatively re-
sponsible for the biosynthesis and incorporation of the
AHBA side chain. We recently reported on the biosynthe-
sis of the AHBA side chain by five of these enzymes via an
acyl carrier protein (ACP)-mediated pathway involving
unusual protective biochemistry via g-L-glutamylation of
a potentially nucleophilic primary amine on the ACP-
bound intermediate (Figure 1) [20]. Two B. circulans
genes, btrG and btrH, were proposed to encode proteins
responsible for the transfer of the AHBA side chain to the
aminoglycoside and the removal of the g-L-Glu protective
group.
RESULTS AND DISCUSSION
Sequence Analysis of BtrG and BtrH
BtrG (156 amino acids, 18.1 kDa) is the archetype of the
eponymous BtrG family of proteins, which contain the
functionally uncharacterized COG2105 domain architec-
ture. The nearest homologs to BtrG are found in other Ba-
cillus species. Structural homologs of BtrG have been
characterized by X-ray crystallography [22, 23] and NMR
(PDB: 1XHS); however, no homolog has been assigned a
proposed function, nor does the observed fold hint at
any specific catalytic activity. The monomer mass of380 Chemistry & Biology 14, 379–386, April 2007 ª2007 ElseviN-terminally His6-tagged BtrG is 20,093 Da by LC-ESI-
MS (calculated at 20,093.38). The deduced amino acid se-
quence of BtrH (302 amino acids, 35.9 kDa) exhibits weak
similarity [24] (25% identity, 39% similarity over 266 amino
acids) only to the uncharacterized hypothetical protein
product of the gene api78 from an identified pathogenicity
island in Yersinia pseudotuberculosis [25]. The N-termi-
nally His6-tagged BtrH exhibits a monomer mass of
37,916 Da (calculated at 37,916.91) by LC-ESI-MS.
Functional Characterization of BtrG and BtrH
In order to facilitate the functional characterization of
these two enzymes, it was desirable to synthetically pre-
pare the acyl-S-BtrI substrate for the acyl transfer reaction
(Figure 2). g-L-Glu-AHBA-CoA was synthesized from
appropriately protected L-glutamate by p-nitrophenyl-
chloroformate-activated ligation to AHBA [26]. The prod-
uct dipeptide was ligated via its N-hydroxysuccinamoyl
ester to coenzyme A [27], and deprotection in TFA yielded
the desired CoA. g-L-Glu-AHBA-CoA was loaded onto
apo-BtrI by the broad-spectrum phosphopantetheinyl
transferase Sfp from Bacillus subtilis [28], yielding directly
g-L-Glu-AHBA-S-BtrI, identical to the species obtained by
incubation of holo-BtrI with BtrJ, BtrK, BtrO, and BtrV in
the presence of L-glutamate, ATP, FMN, and NADH [20].Figure 2. Synthesis of g-L-Glu-AHBA-
CoA
(a) p-nitrophenylchloroformate, Et3N, DMAP;
(b) AHBA, Et3N; (c) DCC, N-hydroxysuccini-
mide; (d) coenzyme A, Li2CO3; (e) trifluoro-
acetic acid.er Ltd All rights reserved
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Total ion current (top) and mass spectrum (bottom) traces showing conversion of ribostamycin to butirosin by BtrG and BtrH.Incubation of g-L-Glu-AHBA-S-BtrI with heterologously
expressed BtrG and BtrH in the presence of ribostamycin
yields authentic butirosin as judged by ion-pairing LC-ESI-
MS/MS analysis (Figure 3; and see the Supplemental Data
available with this article online), confirming the proposed
roles of BtrG and BtrH as the last two enzymes in butirosin
biosynthesis.
Incubation of BtrH with g-L-Glu-AHBA-S-BtrI and ribos-
tamycin yields a new product of mass 685.4 Da by ion-
pairing LC-ESI-MS/MS (Figure 4). This mass and the
observed mass fragmentations (Supplemental Data) are
consistent with g-L-Glu-butirosin ([M+H]+ calculated at
685.32). This result assigns BtrH as the expected amino-
glycoside 1-N-acyltransferase responsible for the ligation
of the side chain in butirosin and demonstrates that acyl
transfer precedes deglutamylation, consistent with the
characterization of the g-glutamyl moiety as a protective
group. The aminoglycoside acetyltransferases (AACs)
are obvious functional relatives of BtrH. Crystal structures
determined for AAC-3 from Serratia marcescens [29] and
AAC-60 from Enterococcus faecium [30] reveal these two
enzymes to share a common fold. These AACs also exhibit
good sequence similarity (33% identity, 53% similarity
over 71 residues) by pairwise alignment. However, BtrH
exhibits no sequence similarity to any AACs and doesChemistry & Biology 14not contain any known conserved domains [31]. This ap-
parent lack of homology is rationalized by the fact that
BtrH (1) utilizes a long dipeptide acyl donor substrate,
whereas the AACs utilize a short acetyl substrate, and
(2) transfers the acyl chain from an ACP, whereas the
AACs utilize acetyl-CoA. Therefore, BtrH may represent
a novel aminoglycoside acyltransferase.
The efficient production of g-L-Glu-butirosin by BtrH in
the absence of BtrG demonstrates that BtrG is responsi-
ble for the deprotection of the g-L-Glu-AHBA side chain
following transfer onto ribostamycin. This order of opera-
tions is further supported by the observation that incuba-
tion of g-L-Glu-AHBA-S-BtrI with BtrG alone does not lead
to generation of AHBA-S-BtrI (data not shown). Function-
ally, BtrG resembles PuuD, the g-glutamyl-g-amino-
butyrate hydrolase involved in the putrescine utilization
pathway of E. coli K12 [32, 33]. However, BtrG bears no
sequence similarity to PuuD, suggesting that it might em-
ploy a different mechanism for cleavage of the g-L-Glu
protective group.While PuuD is thought to employ a water
molecule as nucleophile in a hydrolytic mechanism, it was
proposed that BtrG might instead act as a cyclotransfer-
ase, cleaving the amide bond via transamidation using
the a-amine of g-L-Glu to yield butirosin and pyro-
glutamate as products. This hypothesis was tested by, 379–386, April 2007 ª2007 Elsevier Ltd All rights reserved 381
Chemistry & Biology
Addition of the Amino Acid Side Chain in Butirosinion-pairing LC-ESI-MS/MS using selective reaction
monitoring (SRM) for the neutral deformylation of pyro-
glutamate (m/z 130 / 84) [34]. Assays of BtrG with
BtrH, g-L-Glu-AHBA-S-BtrI, and ribostamycin showed
a peak under SRMat the same retention time as a pyroglu-
tamate standard (Figure 5), while no such peak was seen
Figure 4. Acyltransferase Activity of BtrH
Total ion current and mass spectrum traces showing conversion of
ribostamycin to g-L-Glu-butirosin by BtrH.382 Chemistry & Biology 14, 379–386, April 2007 ª2007 Elseviin control experiments lacking BtrI, BtrH, or ribostamycin,
or in standards of L-glutamate. BtrG is therefore assigned
as a novel g-glutamyl cyclotransferase (GGC).
This activity is comparable to the GGCactivity observed
in the g-glutamyl cycle related to glutathione metabolism
and amino acid transport [35, 36]. In this cycle, g-glutamy-
lated a-amino acids are digested to give pyroglutamate
and the liberated amino acid. Interestingly, while the
activity of this GGC has been extensively characterized
in both tissue extracts and purified enzyme preparations
(25 kDa) [36, 37], neither gene nor peptide sequence
for this enzyme is known to date (though an observed ge-
netic polymorphism has isolated the GGC gene in mice to
a region on chromosome 6 [38]). Further, a functionally
similar g-glutamylamine cyclotransferase (GGAC) enzyme
has been identified in rabbit kidney which is separable
from GGC and which exhibits differing substrate specific-
ity [39]. It is hoped that the functional characterization of
BtrG might lead to the positive identification of the GGC
and GGAC genes. While these results are consistent
with the proposed cyclizing transamidation of the sub-
strate directly, an alternative mechanism involving initial
formation of a g-L-glutamyl-BtrG intermediate followed
by pyroglutamate release cannot be excluded, and stud-
ies into the reaction mechanism of BtrG are ongoing.
Timing of Side Chain Transfer
With the functional assignments of BtrG and BtrH, the
complete pathway for the biosynthesis and incorporation
of the valuable AHBA side chain in butirosin has been fully
elucidated. To verify the timing of side chain addition in
this biosynthetic pathway, the activity of BtrH was as-
sayed toward the major intermediates in the biosynthesis
of the aminoglycoside scaffold. Of the biosynthetic pre-
cursors of ribostamycin, 2-DOS and paromamine are not
substrates for BtrH. Neamine is acylated by BtrH, though
less efficiently than ribostamycin (Supplemental Data),
and no acylation of neamine is observed in a competitive
assay with ribostamycin. This result is in keeping with the
fact that AHBA-neamine has not been observed in
cultures of B. circulans and has only been previously
accessed by acid degradation of butirosin [40, 41]. Thus,
ribostamycin is the preferred natural substrate for BtrH,
supporting the original assignment of side chain addition
as the final step in butirosin biosynthesis [20].
Formation of Alternative Aminoglycoside Products
In order to explore opportunities to apply this pathway to
the preparation of new and potentially useful antibiotics,
the tolerance of BtrG and BtrH for alternative aminoglyco-
side acceptors was investigated. In addition to ribostamy-
cin, BtrH accepts the related 4,5-disubstituted amino-
glycosides paromomycin and neomycin (Figure 6 and
Supplemental Data), but not the 4,6-disubstituted amino-
glycosides gentamicin C or kanamycin. Again, alternative
substrates are processed with diminished efficiency rela-
tive to the natural substrate, ribostamycin. All g-L-Glu-
AHBA-aminoglycosides produced by BtrH are cleaved
to the corresponding AHBA-aminoglycoside by BtrG,er Ltd All rights reserved
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Addition of the Amino Acid Side Chain in ButirosinFigure 5. g-Glutamyl Cyclotransferase Activity of BtrG
(A) Proposed mechanism of deglutamylation by BtrG.
(B) Selective reaction monitoring (SRM) trace demonstrating evolution of pyroglutamate in the course of deprotection.indicating good substrate tolerance for this enzyme
(Supplemental Data). While AHBA-paromomycin [42]
and AHBA-neomycin [43] have been previously prepared
by synthetic acylation of the parent natural product, these
compounds were accessible only in low yield due to the
difficulty of selectively acylating only the C-1 amine in
the presence of several other nucleophilic groups. Biosyn-
thetic preparation is an attractive alternative route toward
these unnatural compounds, which are reported to have
valuable antibiotic properties, particularly toward Pseudo-
monas aeruginosa. These results encourage attempts
toward the engineered biosynthesis of both known and
novel AHBA-bearing aminoglycosides.
SIGNIFICANCE
The pathway for ACP-mediated biosynthesis and
transfer of the valuable (S)-4-amino-2-hydroxybuty-
rate (AHBA) side chain in butirosin has been com-
pletely elucidated. This pathway includes unusual
protection/deprotection chemistry in the form of the
g-L-glutamylation of a potentially labile ACP-bound in-
termediate, transfer of the protected, fully elaborated
side chain to ribostamycin by the acyltransferase
BtrH, and intramolecular cyclic deglutamylation of
the product by the g-glutamyl cyclotransferase BtrG.
The transfer and deprotection of the AHBA side chain
constitute the final steps in the biosynthesis of
butirosin. The catalytic activity of BtrG is of particular
interest as it is, to our knowledge, the first enzyme
containing the COG2105 domain architecture to be
functionally characterized and may lead to the dis-
covery of interesting biosynthetic chemistry in otherChemistry & Biology 14,organisms. BtrG and BtrH are capable of acting on
nonnative aminoglycoside substrates, raising the
prospect for engineered biosynthesis of novel AHBA-
bearing aminoglycosides.
EXPERIMENTAL PROCEDURES
Aminoglycosides were purchased from Sigma-Aldrich, with the ex-
ception of 2-DOS, paromamine, and neamine, which were prepared
according to reported methods [44]. Acetonitrile (MeCN) for HPLC
was purchased from Fisher. HPLC buffer additives trifluoroacetic
acid (TFA), pentafluoropropionic acid (PFPA), and pentadecafluoro-
octanoic acid (PDFOA) were purchased from Sigma-Aldrich. All other
chemicals were purchased from Sigma-Aldrich unless otherwise
stated.
Cloning of btrG and btrH Genes
The genes btrG and btrHwere amplified by PCR from genomic DNA of
Bacillus circulansNR3312 using the following pairs of primers, respec-
tively (restriction sites are underlined): Forward pG1 50-CGTAAGTGAG
TTTAAGCATATGATTAGCTGGACGAA-30 (NdeI) and reverse pG2
50-GCGATTTTCTGCACTCGAGAAATTTCTCGTCATAAC-30 (XhoI); for-
ward pH1 50-AGAGGAGAAGCCATATGTGCCTCACTCGTTATGAC
G-30 (NdeI) and reverse pH2 50-TCCTTCTGTATGGGATCCCGGTTTC
CGCACAGCGGT-30 (BamHI).
PCR reactions were carried out as follows using Pfu polymerase
(Stratagene): 4 min at 94C, then 1 min at 94C, 1 min at 60C, 2 min
at 72C for 25 cycles, final extension at 72C for 10 min. The amplified
genes were cloned into appropriate restriction sites of pET-28a(+)
(Novagen) and transformed into E. coli BL21(DE3) (Novagen) for over-
expression. All constructs were checked by DNA sequencing.
Overexpression and Purification of Recombinant BtrG and BtrH
One liter of culture in LB medium of E. coli BL21(DE3) (Novagen)
harboring recombinant plasmid was grown at 37C for 3 hr with kana-
mycin selection (50 mg/ml). Protein overexpression was induced by
addition of 0.2 mM isopropyl b-D-thiogalactopyranoside (IPTG), and379–386, April 2007 ª2007 Elsevier Ltd All rights reserved 383
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Addition of the Amino Acid Side Chain in ButirosinFigure 6. Acylation and Deprotection of the Unnatural Substrate Neomycin
LC-ESI-MS traces demonstrating the acylation of neomycin by BtrH and the deprotection of the intermediate by BtrG to give AHBA-neomycin.cell growth continued at 16C overnight. Ni2+-NTA affinity chromatog-
raphy purification was performed according to the manufacturer’s
protocols (Novagen). The harvested cells were resuspended in 30 ml
binding buffer (20 mM Tris-HCl [pH 7.9], 0.5 M NaCl, 5 mM imidazole,
10% glycerol) and disrupted by sonication. N-terminally His6-tagged
proteins were purified in one step by Ni2+-NTA affinity column and
exchanged into storage buffer by ultrafiltration. The purified proteins
were stored in 50 mM HEPES (pH 7.0) containing 50% glycerol at
20C.
LC-ESI-MS Analysis of Proteins
LC-ESI-MS analysis of protein samples was performed on a Finnigan
LCQ (Thermo Finnigan) coupled with an HP1100 HPLC system
(Agilent). Samples were separated on a 2.0 3 250 mm Jupiter 5m C4
column (Phenomenex) by the following gradient at a flow rate of
0.2 ml/min and column temperature of 40C: 0–5 min 5% B, 5–6 min
5%–35% B, 6–31 min 35%–65% B, 31–36 min 65% B, 36–41 min
65%–95% B (buffer A: 0.1% TFA in H2O; buffer B: 0.1% TFA in
MeCN). Absorbance was monitored at 214 nm. Mass spectra were
acquired from 200 to 2000 Da.
Synthesis of N-Boc-a-tert-Butyl-g-L-Glu-AHBA Dipeptide
N-Boc-L-glutamic acid a-tert-butyl ester (0.25 mmol) was dissolved in
5ml acetonitrile under nitrogen. The solution was cooled in an ice bath,
and triethylamine (0.4 mmol), p-nitrophenylchloroformate (0.3 mmol)
and 4-dimethylaminopyridine (0.02 mmol) were added. After 1 hr,384 Chemistry & Biology 14, 379–386, April 2007 ª2007 Elsevie(S)-4-amino-2-hydroxybutyric acid (1 mmol) and triethylamine
(1.05 mmol) were dissolved in 5 ml H2O and added dropwise to the
reaction. The reaction stirred for 1 hr at room temperature, and then
acetonitrile was removed by evaporation. The remaining solution
was stirred vigorously with 20 ml ethyl acetate and acidified to pH
2 with 1 M HCl. The organic phase was separated and the aqueous
layer was washed twice with 20 ml ethyl acetate. Organic extracts
were dried over magnesium sulfate, filtered, and dried by evaporation.
The residue was taken up in 5 ml ethyl acetate, and the product was
precipitated by addition of 20–30 PET ether. The precipitate was
collected by centrifugation, dissolved in methanol, and evaporated
to give 65 mg (0.16 mmol, 64%) of product as a fluffy white solid.
Synthesis of g-L-Glu-AHBA-CoA
N-Boc-a-tert-butyl-g-L-Glu-AHBA dipeptide (13.5 mmol), N,N0-
dicyclohexylcarbodiimide (17.0 mmol), and N-hydroxysuccinimide
(26.0 mmol) were dissolved in 1.5 ml acetonitrile under nitrogen. The
reaction was stirred overnight at room temperature, and then coen-
zyme A (20.4 mmol) was dissolved in 0.25 ml of 40 mM aqueous lithium
carbonate and added dropwise to the reaction. After stirring at room
temperature for 4 hr, the reaction mixture was subjected directly to
preparative HPLC on a 21.2 3 250 mm Luna 10m C18(2) column
(Phenomenex) by the following gradient at a flow rate of 15 ml/min at
room temperature: 0–5 min 5% B, 5–25 min 5%–40% B, 25–27 min
40%–95% B, 27–30 min 95% B (buffer A: 0.1% TFA in H2O; buffer
B: 0.1% TFA in MeCN). Absorbance was monitored at 254 nm andr Ltd All rights reserved
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by evaporation, and water was removed by lyophilization.
The dried residue was dissolved in 1 ml of trifluoroacetic acid:H2O:
triisopropylsilane (95:2.5:2.5) under nitrogen and stirred at room tem-
perature for 2 hr. The product was precipitated by addition of 10 ml
ice-cold ether and collected by centrifugation. The precipitate was
taken up in H2O and lyophilized to give 3 mg (3.0 mmol, 22% over
two steps) product.
40-Phosphopantetheinylation of apo-BtrI
A reaction mixture (total volume 10 mL) containing 50 mM HEPES (pH
6.5), 1 mM g-L-Glu-AHBA-CoA, 1 mM MgCl2, 0.3 nmol Sfp, and
1.5 nmol apo-BtrI was incubated at 37C for 30 min and analyzed
directly by LC-ESI-MS.
Enzymatic Assays of BtrH
The acyltransferase activity of BtrH was assayed in a typical 30 ml re-
action containing 50 mM HEPES (pH 6.5), 1 mM g-L-Glu-AHBA-CoA,
1 mM aminoglycoside, 0.3 nmol BtrH, 0.3 nmol Sfp, and 1.5 nmol
apo-BtrI. The reaction was incubated at 37C for 1.5 hr. Proteins
were precipitated by heating to 95C for 5–10 min followed by vortex-
ing with 30 ml chloroform and centrifugation. The clear aqueous layer
was taken for LC-ESI-MS/MS analysis. Samples were separated on
a 2.03 250mm Luna 5mC18(2) column (Phenomenex) by the following
gradient at a flow rate of 0.3 ml/min and column temperature of 40C:
0–20 min 10%–50% B, 20–21 min 50%–10% B, 21–25 min 10% B
(buffer A: 0.1% PFPA in H2O; buffer B: 0.1% PFPA in MeCN). Mass
spectra were acquired from 300 to 1000 Da (except for assays with
2-DOS as aminoglycoside acceptor, in which case mass spectra
were acquired from 150 to 1000 Da). MS/MS was carried out on target
ions with 20% relative collision energy (helium as collision gas).
Enzymatic Assays of BtrG
The deglutamylating activity of BtrG was assayed in a typical 30 ml
reaction as above, with the addition of 60–70 pmol BtrG.
Determination of Pyroglutamate Formation by BtrG
A typical 30 ml BtrG assay was incubated and worked up as described
above, except samples were not heat-denatured prior to chloroform
precipitation to avoid potential nonenzymatic cyclization of glutamate.
Samples were separated on a 2.0 3 250 mm Luna 5m C18(2) column
(Phenomenex) by the following gradient at a flow rate of 0.25 ml/min
and column temperature of 40C: 0–4 min 5% B, 4–7 min 5%–45%
B, 7–9 min 45% B, 9–10 min 45%–5% B (buffer A: 1 mM PDFOA
and 0.05% TFA in H2O; buffer B: 1 mM PDFOA and 0.05% TFA in
MeCN). Mass spectra were acquired with selective reaction monitor-
ing for the neutral deformylation of pyroglutamate (m/z 130/ 84).
Supplemental Data
Supplemental Data include four figures and are available at http://
www.chembiol.com/cgi/content/full/14/4/379/DC1/.
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